Delving into the Latest Updates on Benovus Bio, Inc. with Synapse

Overview

The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels. The peptides stimulate cytotoxic T-cells targeting oncofetal antigen (OFA). Subjects with AML, MM, sMM, or MDS who are off treatment and with stable disease or better, or who are not eligible for or refuse allogeneic HSCT are to be enrolled. The study will be conducted at 2 to 4 study centers in the US.

Start Date01 Jan 2015

Sponsor / Collaborator

Benovus Bio, Inc.

100 Clinical Results associated with Benovus Bio, Inc.

Login to view more data

0 Patents (Medical) associated with Benovus Bio, Inc.

Login to view more data

100 Deals associated with Benovus Bio, Inc.

Login to view more data

100 Translational Medicine associated with Benovus Bio, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

8

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

OFA-3 ( 30S subunit )	Neoplasms More	Discontinued
OFA-1 ( 30S subunit )	Neoplasms More	Discontinued
OFA-2 ( 30S subunit )	Neoplasms More	Discontinued
BB-MPI-03	Acute Myeloid Leukemia More	Pending
BV-27	Neoplasms More	Pending